| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.18 | 0.003 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.098 | 0.003 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.004 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.088 | 0.004 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.006 |